Cancer immunotherapy has emerged as a revolutionary approach in the treatment of various malignancies, harnessing the power of the immune system to target and eliminate cancer cells. Among the innovative strategies within this field, Bispecific T-cell Engagers (BiTEs) represent a cutting-edge technology designed to recruit and activate T-cells, the body's primary immune effector cells, to specifically target and kill tumor cells. BiTEs exemplify the concept of redirecting the immune system's intrinsic capabilities toward malignant cells by leveraging the specificity of antibodies and the potent cytotoxic functions of T-cells.